研究人员和企业也在努力开发人工抗体,注射进人体后,人工抗体会在CGRP抵达感应器官之前拦截血液或大脑中的CGRP,或者屏蔽感应器官。
Research into these biologic antibody-based approaches is at an earlier stage than the testing of antagonist drugs, but antibodies eventually might be able to block CGRP action regularly so that migraines don't ever begin.
对于这类基于生物抗体的方法的研究处于早期,还未达到拮抗药物的测试阶段,但是抗体也许最终能够规律性地阻止CGRP的活动,使偏头痛无从发作。
'The CGRP story is a story of developing an acute treatment for migraine,' says Dr. Goadsby. 'But the antibody story is testing the larger idea [that] if you blocked continuously CGRP, would you have a preventive treatment.'
“CGRP之说涉及到偏头痛紧急治疗方法的开发,”戈德比医生说,“但是对抗体的研究实际上是就更重要的理念展开测试,即如果不断阻止CGRP,就会是一种预防性的治疗手段。”
【难治的偏头痛让科学家头痛】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15